Tradestie Institutional Equity Comparison Engine
NDRA vs MBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NDRA Overall Edge
NDRA Captures Institutional Edge (1โ1 Pillars ยท 3โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ENDRA Life Sciences Inc. Common Stock (NDRA) driven by superior Momentum & Technical while MBIO counters with relative strength in Growth & Margin. Fundamentally, NDRA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MBIO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, NDRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
NDRA N/M vs MBIO N/M Fwd P/E
Growth & Margin Winner
MBIO
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
NDRA
1Y -32.7% vs -67.4% ยท 52W Pos 37% vs 4%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
NDRA
NASDAQ
ENDRA Life Sciences Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
+0.23% 1D
Market Cap
$6.6M
1M Return
-6.75%
1Y Return
-32.72%
Forward P/E
N/M
Unified AI Score
44.7 / 100
HOLD
Tech 35.0
Fund 46.0
Flow 50.0
Mom 60.0
MBIO
NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-6.34% 1D
Market Cap
$3.2M
1M Return
+4.86%
1Y Return
-67.38%
Forward P/E
N/M
Unified AI Score
42.9 / 100
HOLD
Tech 40.0
Fund 49.0
Flow 50.0
Mom 70.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
NDRA -32.72%
MBIO -67.38%
Spread: +34.66 pp (NDRA Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
NDRA TTM Op. Margin: 0.0%
MBIO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NDRA vs MBIO. Trailing 12-month operating profitability (NDRA 0.0% vs MBIO 0.0%) and valuation multiples (NDRA N/M vs MBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NDRA | MBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $6.6M | $3.2M | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -152.0% | -43.1% | Higher ROE | MBIO |
| 52-Week Range Position Momentum | 37% ($3โ$7) | 4% ($0โ$1) | Stronger Trend | NDRA |
| Beta / 30D Volatility Risk Regime | 0.71ฮฒ ยท 48% Vol | 0.66ฮฒ ยท 86% Vol | Lower Realized Risk | NDRA |
| Unified Institutional Score Composite Signal | 44.7 / 100 (HOLD) | 42.9 / 100 (HOLD) | Higher Composite | NDRA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full NDRA vs MBIO Buy Guide
NDRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
MBIO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither NDRA nor MBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.